Is FMT A Drug? Lance Shea, M.S., J.D. Washington Square, Suite Connecticut Ave., NW Washington, DC, D

Size: px
Start display at page:

Download "Is FMT A Drug? Lance Shea, M.S., J.D. Washington Square, Suite Connecticut Ave., NW Washington, DC, D"

Transcription

1 Is FMT A Drug? Lance Shea, M.S., J.D. Washington Square, Suite Connecticut Ave., NW Washington, DC, D LShea@bakerlaw.com

2 FMT Scenarios Intra-Office Bank Product

3 The Issue The FDA s decision to regulate fecal microbiota as a drug has both positive and negative consequences. Broadly speaking, there is a clear need for oversight of the use of fecal microbiota for transplantation, given the risks posed by stool-borne transmissible illnesses...

4 The Issue The uniformity and expertise that the FDA can offer the industry are important institutional advantages both for stool providers navigating their legal responsibilities and for physicians seeking guidance on how to best help their patients. Sachs 2015 at 398.

5 The Issue However, the FDA s decision has proven problematic... Not only does stool defy the typical scientific characterization that the FDA has long applied to small molecule and biologic drugs,...

6 The Issue but the potential do-it-yourself nature of the treatment poses particular concerns in the context of a regime involving periods of regulatory exclusivity. The goals of any regulation of FMT for the treatment of recurrent C. diffcile infection should be to optimize access to the therapy while maintaining strict screening and reporting standards and oversight. Id.

7 Road Map What is a drug? What is a biological product? What is exclusivity?

8 What Is A Drug? What products are regulated by the FDA as drugs?

9 Drug (21 U.S.C. 321(g)(1)) The FDCA defines drugs as articles... recognized in the official United States Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; and intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; and (other than food) intended to affect the structure or any function of the body of man or other animals; and intended for use as a component of any article specified [above].

10 Drug (21 U.S.C. 321(g)(1)) The FDCA defines drugs as articles... recognized in the official United States Pharmacopoeia, official Homoeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them; and intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; and (other than food) intended to affect the structure or any function of the body of man or other animals; and intended for use as a component of any article specified [above].

11 Intended Use The FD&C Act defines drugs, in part, by their intended use... Some products... [can have] two intended uses... a shampoo is a cosmetic because its intended use is to cleanse the hair. An antidandruff treatment is a drug because its intended use is to treat dandruff. Consequently, an antidandruff shampoo is both a cosmetic and a drug.

12 Establishing Intended Use Claims stated on the product labeling, in advertising, on the Internet, or in other promotional materials. Consumer perception, which may be established through the product's reputation. Ingredients that cause a product to be considered a drug because they have a well-known (to the public and industry) therapeutic use.

13 New Drug (21 C.F.R. 320(h)) The newness of a drug may arise by reason (among other reasons) of: A new use of a substance of which the drug is composed A new use of a combination of approved drugs A change in the proportions of ingredients in an approved drug A new indication for use A change in dosage, or method or duration of administration or application

14 New... Active moiety means the molecule or ion... responsible for the physiological or pharmacological action of the drug substance. 21 C.F.R (a). New chemical entity means a drug that contains no active moiety that has been approved by FDA in any other application submitted under section 505(b) of the act. 21 C.F.R (a).

15 Prescription Drugs (21 U.S.C. 353(b)) A drug intended for use by man which... is not safe for use except under the supervision of a practitioner licensed by law to administer such drug; or... is limited by an approved application under section 355 of this title to use under the professional supervision of a practitioner licensed by law to administer such drug; shall be dispensed only (i) upon a written prescription... (ii) upon an oral prescription... reduced promptly to writing and filed by the pharmacist, or (iii) by refilling any such written or oral prescription...

16 Over-The-Counter Drugs 1951: Durham-Humphrey Amendment OTC drug characteristics: benefits clearly outweigh possible risks potential for misuse and abuse is low public can use them for self-diagnosed conditions can be labeled to help assure appropriate use by the average person healthcare practitioners are not needed for their safe and effective use

17 What Is A Biological Product

18 Biologic Product (42 U.S.C. 262(i)) The term 'biological product' means... a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein [and others]... applicable to the prevention, treatment, or cure of a disease or condition of human beings.

19 What Is Exclusivity?

20 Exclusivity Exclusivity provides the holder of an approved new drug application limited protection from new competition in the marketplace for the innovation represented by its approved drug product. valprocess/smallbusinessassistance/ucm htm

21 Exclusivity - Drugs 7 years orphan drugs 5 years NCEs 3 years new indications, clinical exclusivity, new populations, new release formulations, new combination products, etc. +6 months pediatric indications +5 years QIDP

22 Exclusivity - Biologicals 12 years BLA +6 months pediatric indications 7 years orphan product 3 years Rx to OTC

23 For Discussion Definition fit Jurisdiction Practicalities of approval/licensure Impact of exclusivity

24 Is FMT A Drug? Lance Shea, M.S., J.D. Washington Square, Suite Connecticut Ave., NW Washington, DC, D LShea@bakerlaw.com

25 Drug Approval Pathways

26 New Drug Approval Pathways Three pathways for marketing approval: 505(b)(1) New drug (RLD) 505(b)(2) Generic not identical to the RLD 505(j) Generic identical to the RLD

27 Three Drug Approval Pathways 505(b)(1): Application contains full reports of investigations of safety and effectiveness New drugs Brand drug a/k/a reference listed drug (RLD) RLD: The listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA (21 C.F.R (a)(3))

28 Three Drug Approval Pathways 505(b)(2): The later drug is not identical to the RLD and differences between them are not insubstantial. Information required for approval, to cover the differences, comes from studies not conducted by or for the RLD applicant. The identical features are covered by data in the RLD NDA, where the 505(b)(2) sponsor has obtained a right of reference.

29 Three Drug Approval Pathways 505(j): Application contains information to show that the proposed product is identical... In active ingredient, dosage form, strength, route of administration, labeling, quality, performance characteristics, and intended use, among other things... to a previously approved product.

30 Biologics Licensure Pathways

31 Biologics Price Competition and Innovation Act of 2009 Two types of biological product applications: 351(a) Original BLA 351(k) Biosimilar BLA

32 Dietary Supplement (21 U.S.C. 321(ff)) The FDCA defines dietary supplement as a product (other than tobacco) intended to supplement the diet that bears or contains one or more of the following dietary ingredients: a vitamin a mineral an herb or other botanical an amino acid A dietary substance for use by man to supplement the diet by increasing the total dietary intake and more

33 Dietary Supplement v. Food ( Conventional foods are foods that are not dietary supplements. Dietary supplements must be labeled as such and must not be represented for use as a conventional food or as the sole item of a meal or the diet. One way to distinguish dietary supplements from conventional foods is by looking at the nutrition information on the label of the product. Conventional foods must have a Nutrition Facts panel on their labels, but dietary supplements must have a Supplement Facts panel.

34 Device (21 U.S.C. 321(h)) The FDCA defines device as an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is recognized in the official National Formulary, or the United States Pharmacopeia, or any supplement to them, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or intended to affect the structure or any function of the body of man or other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes.

35 Device v. Drug ( Device/ucm htm) Bracco Pharmaceuticals case If the primary intended use of the product is achieved through chemical action or by being metabolized by the body, the product is usually a drug.

Office for Human Subject Protection. University of Rochester

Office for Human Subject Protection. University of Rochester POLICY 1. Purpose Outline the responsibilities and regulatory requirements when conducting human subject research that involves the use of drugs, agents, biological products, or nutritional products (e.g.,

More information

Regulation of Microbiota- Based Products

Regulation of Microbiota- Based Products Regulation of Microbiota- Based Products LCDR Matthew Steele, PhD Team Leader, Regulatory Review Branch 1 Division of Vaccines and Related Products Applications CBER/OVRR My presentation is an informal

More information

Combination Products at US FDA

Combination Products at US FDA Multimodal Therapies for Brain Disorders: Session II Regulatory and Reimbursement Considerations Combination Products at US FDA Patricia Y. Love, MD, MBA Deputy Director Office of Combination Products,

More information

MOBILE MEDICAL APPLICATIONS REVIEWING FDA GUIDANCE FOR INDUSTRY USE

MOBILE MEDICAL APPLICATIONS REVIEWING FDA GUIDANCE FOR INDUSTRY USE MOBILE MEDICAL APPLICATIONS REVIEWING FDA GUIDANCE FOR INDUSTRY USE Mike Vanderboom, JD Contract Analyst Office of Grants & Contracts The Medical College of Wisconsin, Inc. 1 Introduction Mobile Applications,

More information

POLICY AND PROCEDURES. Office of Pharmaceutical Quality. Table of Contents

POLICY AND PROCEDURES. Office of Pharmaceutical Quality. Table of Contents POLICY AND PROCEDURES Office of Pharmaceutical Quality NDA Classification Codes Table of Contents PURPOSE...1 BACKGROUND...1 POLICY...1 NDA Classification Codes...2 RESPONSIBILITIES...7 REFERENCES...9

More information

Title: Department: Approved by: Director, Human Research Review and Compliance

Title: Department: Approved by: Director, Human Research Review and Compliance Title: Department: Requirements for Investigational New Drug (IND) for Human- Subjects Research Human Research Affairs Policy Type: Partners System-wide Partners System-wide Template Partners HealthCare

More information

13 FDA-Regulated Research

13 FDA-Regulated Research 13 FDA-Regulated Research FDA regulations apply to research that involves a FDA-regulated test article in a clinical investigation involving human subjects as defined by the FDA regulations. For FDA-regulated

More information

Draft Guidance for Industry, Clinical Laboratories, and FDA Staff. In Vitro Diagnostic Multivariate Index Assays

Draft Guidance for Industry, Clinical Laboratories, and FDA Staff. In Vitro Diagnostic Multivariate Index Assays Draft Guidance for Industry, Clinical Laboratories, and FDA Staff In Vitro Diagnostic Multivariate Index Assays DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Document

More information

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited. Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics

More information

Draft Guidance for Industry and FDA Staff Premarket Notification [510(k)] Submissions for Medical Devices that Include Antimicrobial Agents

Draft Guidance for Industry and FDA Staff Premarket Notification [510(k)] Submissions for Medical Devices that Include Antimicrobial Agents Draft Guidance for Industry and FDA Staff Premarket Notification [0(k)] Submissions for Medical Devices that Include Antimicrobial Agents DRAFT GUIDANCE This guidance document is being distributed for

More information

STIMULI TO THE REVISION PROCESS

STIMULI TO THE REVISION PROCESS Page 1 of 6 STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts USP's Nomenclature Initiatives Angela G. Long, M.S.; Andrzej

More information

Device research sponsors, whether companies or investigators, are held responsible for meeting the same regulations.

Device research sponsors, whether companies or investigators, are held responsible for meeting the same regulations. POLICY #: RCO-101 Page: 1 of 11 1. POLICY STATEMENT: A DF/HCC Investigator who holds an Investigational Device Exemption (IDE) or who is the Sponsor of the research has additional responsibilities that

More information

3.1. Overall Principal Investigator (PI), who holds the IDE and/or is the Sponsor

3.1. Overall Principal Investigator (PI), who holds the IDE and/or is the Sponsor POLICY #: RCO-101 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational Device Exemption (IDE) or who is the Sponsor of the research has additional responsibilities

More information

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.

Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited. Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited. Special Review Designations & Approval Pathways Special Designations

More information

Interpretation of the Deemed to be a License Provision of the Biologics Price Competition and Innovation Act of 2009

Interpretation of the Deemed to be a License Provision of the Biologics Price Competition and Innovation Act of 2009 Interpretation of the Deemed to be a License Provision of the Biologics Price Competition and Innovation Act of 2009 Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration

More information

The Deemed to be a License Provision of the BPCI Act Questions and Answers Guidance for Industry

The Deemed to be a License Provision of the BPCI Act Questions and Answers Guidance for Industry The Deemed to be a License Provision of the BPCI Act Questions and Answers Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions

More information

Revision: 00 Page 1 of 6 Date:

Revision: 00 Page 1 of 6 Date: INSPECTION GUIDELINE TITLE: GUIDELINES FOR INSPECTION OF IMPORTED MEDICAL DEVICES, FOOD SUPPLEMENTS, MEDICAL COSMETICS, HERBAL PRODUCTS AND OTHER BORDERLINE PRODUCTS AUTHOR: KEBS AND PPB NO. OF APPENDICES:

More information

CGMP Requirements for Investigational Products

CGMP Requirements for Investigational Products PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health

More information

NEW YORK STATE BAR ASSOCIATION FOOD, DRUG AND COSMETIC LAW SECTION AND HEALTH LAW SECTION COMMITTEE ON MEDICAL RESEARCH AND BIOTECHNOLOGY

NEW YORK STATE BAR ASSOCIATION FOOD, DRUG AND COSMETIC LAW SECTION AND HEALTH LAW SECTION COMMITTEE ON MEDICAL RESEARCH AND BIOTECHNOLOGY NEW YORK STATE BAR ASSOCIATION FOOD, DRUG AND COSMETIC LAW SECTION AND HEALTH LAW SECTION COMMITTEE ON MEDICAL RESEARCH AND BIOTECHNOLOGY MEMORANDUM IN SUPPORT OF AN AMENDMENT TO NEW YORK S PHARMACY LAW

More information

Title: Review of Medical Devices Page: 1 of 5 Written by:

Title: Review of Medical Devices Page: 1 of 5 Written by: THE NORTH SHORE MEDICAL CENTER Institutional Review Board (IRB) POLICIES AND PROCEDURES IRB Policy Number: 031.1 Title: Review of Medical Devices Page: 1 of 5 Written by: Approved by: Laura W. Knight,

More information

Structure and Mandate of FDA

Structure and Mandate of FDA Structure and Mandate of FDA Leonard Sacks, M.D. Office of Medical Policy Center for Drug Evaluation and Research FDA FDA Clinical Investigator Training Course November 13, 2018 Mission of regulatory agencies

More information

FDA-Regulated Research

FDA-Regulated Research Chapter 18: FDA-Regulated Research Chapter Contents 18.1 FDA-Regulated Research 18.2 Investigational Drugs 18.3 Investigational Medical Devices 18.4 Sponsor-Investigators 18.5 Humanitarian Use Devices

More information

FDA 101 Session: Care and Feeding of an Investigational New Drug (IND)

FDA 101 Session: Care and Feeding of an Investigational New Drug (IND) FDA 101 Session: Care and Feeding of an Investigational New Drug (IND) CAPT Kofi Ansah, PharmD, MS, MBA, RAC CAPT William Bender, RPh, MSHCA, RAC CDR Keith Kiedrow, PharmD, MS, RAC CDR Hiren Patel, PharmD,

More information

IRB APPLICATION OF FDA REGULATIONS Click for Animation

IRB APPLICATION OF FDA REGULATIONS Click for Animation IRB APPLICATION OF FDA REGULATIONS Click for Animation Created 12/2016 Belinda Smith & Jennifer Hill, University of Kentucky Office of Research Integrity Acknowledgement Ada Sue Selwitz FDA IRB Review

More information

The Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement

The Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement Page: 1 of 8 I. PURPOSE II. III. IV. The purpose of this Standard Operating Procedure is to delineate when an investigator must obtain an Investigational New Drug (IND) or Investigational Device Exemption

More information

New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 2)

New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 2) New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 2) Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and

More information

Nonproprietary Naming of Biological Products

Nonproprietary Naming of Biological Products Nonproprietary Naming of Biological Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document

More information

Food and Drug Administration (FDA) 101

Food and Drug Administration (FDA) 101 Food and Drug Administration (FDA) 101 What is the Food and Drug Administration (FDA)? The FDA is an agency within the U.S. Department of Health and Human Services that is responsible for protecting the

More information

Introduction to the FDA. Historical Context. Changes over Time FDA - BE-200 9/23/2004. Copyright C. S. Tritt, Ph.D. 1

Introduction to the FDA. Historical Context. Changes over Time FDA - BE-200 9/23/2004. Copyright C. S. Tritt, Ph.D. 1 Introduction to the FDA C. S. Tritt, Ph.D. October 21, 2003 Historical Context In the early 1900 s people were being ripped off, made sick and even killed by bad food, patent medicines and cosmetics with

More information

Guidance for Industry Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act

Guidance for Industry Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act Guidance for Industry Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act DRAFT GUIDANCE This guidance document is being distributed for comment purposes only.

More information

Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act

Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry U.S. Department of Health and Human Services Food and Drug

More information

Question Yes No. 1. Is the study interventional (a clinical trial)? Study Type data element is Interventional

Question Yes No. 1. Is the study interventional (a clinical trial)? Study Type data element is Interventional Checklist for Evaluating Whether a Clinical Trial or Study is an Applicable Clinical Trial (ACT) Under 42 CFR 11.22(b) for Clinical Trials Initiated on or After January 18, 2017 1 (NOT FOR SUBMISSION 2

More information

Navigating the FDA, and understanding Medical Device Preemption. Special Counsel Foulston Siefkin

Navigating the FDA, and understanding Medical Device Preemption. Special Counsel Foulston Siefkin Navigating the FDA, and understanding Medical Device Preemption Presented by Cydney Boler Special Counsel Foulston Siefkin cboler@foulston.com 913-253-2158 March 9, 2010 A bit of Legalese upfront: The

More information

Drug Development and Incrementally Modified Drugs : Regulatory Perspective. American Association of Pharmaceutical Scientists October 27, 2015

Drug Development and Incrementally Modified Drugs : Regulatory Perspective. American Association of Pharmaceutical Scientists October 27, 2015 Drug Development and Incrementally Modified Drugs : Regulatory Perspective American Association of Pharmaceutical Scientists October 27, 2015 Larissa Lapteva, M.D., M.H.S., Division of Therapeutic Performance

More information

1 Purpose. 2 Procedure. Title: FDA-Regulated Research. SOP Number: 1301 Effective Date: June 2, Previous Version Dates:

1 Purpose. 2 Procedure. Title: FDA-Regulated Research. SOP Number: 1301 Effective Date: June 2, Previous Version Dates: Previous Version Dates: Title: FDA-Regulated Research SOP Number: 1301 Effective Date: June 2, 2017 1 Purpose FDA regulations apply to research that involves a FDA-regulated test article in a clinical

More information

Pediatric Exclusivity and Drug Development Requirements in the Overall Pediatric Population. Prepared by Beckloff Associates, Inc.

Pediatric Exclusivity and Drug Development Requirements in the Overall Pediatric Population. Prepared by Beckloff Associates, Inc. and Drug Development Requirements in the Overall Pediatric Population 1 INTRODUCTION AND OVERVIEW Prepared by Beckloff Associates, Inc. Although children suffer from many of the same diseases as adults

More information

Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009

Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 Guidance for Industry U.S. Department of Health and Human Services Food and Drug

More information

INSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND)

INSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND) INSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND) (The field numbers below correspond to the numbered boxes on the Form FDA 1571) Field 1: NAME OF SPONSOR The sponsor

More information

INSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND)

INSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND) INSTRUCTIONS FOR FILLING OUT FORM FDA 1571 INVESTIGATIONAL NEW DRUG APPLICATION (IND) (The field numbers below correspond to the numbered boxes on the Form FDA 1571) Field 1: NAME OF SPONSOR The sponsor

More information

Guidance for Industry New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products

Guidance for Industry New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products Guidance for Industry New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Cooperative Manufacturing Arrangements for Licensed Biologics Additional copies of this guidance are available from the Office of Communication, Training and Manufacturers Assistance

More information

I. Purpose. II. Definitions. Last Approval Date

I. Purpose. II. Definitions. Last Approval Date Investigational Drugs and Biologics Page 1 of 13 I. Purpose The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics

More information

Saudi Pharmacist Licensure Examination (SPLE)

Saudi Pharmacist Licensure Examination (SPLE) Saudi Pharmacist Licensure Examination (SPLE) 1 SPLE Overview This document provides important information about the topics covered on the examination and the competency areas in which candidates will

More information

Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act

Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act Guidance for Industry U.S. Department of Health and Human Services Food and Drug

More information

Glossary of Abbreviations

Glossary of Abbreviations Glossary of Abbreviations ANDA APhA Abbreviated New Drug Application American Pharmaceutical Association API Active Pharmaceutical Ingredient BA/BE Bioavailability/Bioequivalence BE Bioequivalence Bio

More information

The Institutional Review Board (IRB) Manual

The Institutional Review Board (IRB) Manual The Institutional Review Board (IRB) Manual Investigational Devices Policy Research that involves the use of investigational devices must conform to Food and Drug Administration (FDA) and Department of

More information

FIP STATEMENT OF POLICY Pharmacist's authority in pharmaceutical product selection: therapeutic interchange and substitution

FIP STATEMENT OF POLICY Pharmacist's authority in pharmaceutical product selection: therapeutic interchange and substitution Pharmacist's authority in pharmaceutical product selection: therapeutic interchange and substitution Purpose: The purpose of this document is to provide a set of recommendations on therapeutic interchange

More information

How to put together an IND application

How to put together an IND application How to put together an IND application Judit Milstein, Chief, Project Management Staff Judit.milstein@fda.hhs.gov Eithu Lwin, Regulatory Health Project Manager Eithu.Lwin@fda.hhs.gov Division of Transplant

More information

US FDA: CMC Issues for INDs

US FDA: CMC Issues for INDs ISBTC Global Regulatory Summit October 29, 2008 US FDA: CMC Issues for INDs Keith Wonnacott, Ph.D. keith.wonnacott@fda.hhs.gov US Food and Drug Administration Center for Biologics Evaluation and Research

More information

CONCEPT OF 505 (b) (2) APPLICATION: BENEFITS AND CHALLENGES

CONCEPT OF 505 (b) (2) APPLICATION: BENEFITS AND CHALLENGES CONCEPT OF 505 (b) (2) APPLICATION: BENEFITS AND CHALLENGES Available online at www.ijdra.com REVIEW ARTICLE Chaitanya Prasad K*, Prabodh M, Ashish S, Suthakaran R Department of Pharmaceutical Management

More information

Overview of the FDA Approval Process for TB Diagnostics

Overview of the FDA Approval Process for TB Diagnostics Overview of the FDA Approval Process for TB Diagnostics Steven Gitterman, M.D., Ph.D. Division of Microbiology Devices Center for Devices and Radiological Health FDA Definition: In Vitro Diagnostic Device

More information

Investigator s Handbook

Investigator s Handbook Page 96 CHAPTER 11 Investigational Drugs, Agents, Biologics, and Devices Investigational Drugs/Investigational Biologics (Test Articles) A new drug/agent or biologic that is used in a clinical investigation.

More information

Drugs and Medical Devices Regulatory & Industry Overview

Drugs and Medical Devices Regulatory & Industry Overview Drugs and Medical Devices Regulatory & Industry Overview Presented to: Vanderbilt University April 10, 2013 Charles N. (Chuck) Jolly cjolly@bakerdonelson.com Ph. 410.648.5004 or 914-924-0738 (cell) Industry

More information

COMPOUND MEDICATION NON-FORMULARY (QUALIFIED HEALTH PLANS)

COMPOUND MEDICATION NON-FORMULARY (QUALIFIED HEALTH PLANS) COMPOUND MEDICATION NON-FORMULARY (QUALIFIED HEALTH PLANS) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit

More information

Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development

Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development No. 1 of 10 1. regulates all the drugs products manufactured and sold in the USA. (A) EMEA (B) IND (C) FDA (D) NDA (E) OSHA

More information

Interchangeability: What is Next? Analysis of the concept & of the FDA Draft Guidance

Interchangeability: What is Next? Analysis of the concept & of the FDA Draft Guidance Interchangeability: What is Next? Analysis of the concept & of the FDA Draft Guidance Hillel Cohen, Executive Director of Scientific Affairs Leading on Biosimilars: The 2017 AAM Biosimilars Council Conference

More information

Status of Food and Drug Administration Programs and Activities During the Current Government Shutdown

Status of Food and Drug Administration Programs and Activities During the Current Government Shutdown Status of Food and Drug Administration Programs and Activities During the Current Government Shutdown Agency-Wide FDA can perform activities necessary to address imminent threats to the safety of human

More information

Biosimilars: The Impact on Academic Pharmacy

Biosimilars: The Impact on Academic Pharmacy Biosimilars: The Impact on Academic Pharmacy George E. MacKinnon III, PhD, MS, RPh, FASHP Founding Dean and Professor College of Pharmacy Vice Provost for Health Sciences Roosevelt University Learning

More information

Summary of the Actions of the March Virtual House of Delegates. March 16-23, 2018

Summary of the Actions of the March Virtual House of Delegates. March 16-23, 2018 Summary of the Actions of the March Virtual House of Delegates March 16-23, 2018 The House of Delegates Ultimate authority over ASHP professional policies One annual session consisting of 4 meetings: 2

More information

Sec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements.

Sec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements. H.R. 2430, FDA Reauthorization Act of 2017 Section 1. Short Title. This Act may be cited as the FDA Reauthorization Act of 2017. Section 2. Table of Contents Table of Contents TITLE I: FEES RELATING TO

More information

March 4, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

March 4, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852 March 4, 2014 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2013-N-1523: Request for Nominations: Drug Products that

More information

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Document issued on: July 14, 2011

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Document issued on: July 14, 2011 Draft Guidance for Industry and Food and Drug Administration Staff In Vitro Companion Diagnostic Devices DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Document issued

More information

Content Areas of the Pharmacy Curriculum Outcomes Assessment (PCOA )

Content Areas of the Pharmacy Curriculum Outcomes Assessment (PCOA ) Content Areas of the Pharmacy Curriculum Outcomes Assessment (PCOA ) Area 1.0 Basic Biomedical Sciences (10%) Area 2.0 Pharmaceutical Sciences (33%) Area 3.0 Social/Behavioral/Administrative Sciences (22%)

More information

Medical Device Accessories: Defining Accessories and Classification Pathway for New Accessory Types. Draft Guidance for Industry and

Medical Device Accessories: Defining Accessories and Classification Pathway for New Accessory Types. Draft Guidance for Industry and Medical Device Accessories: Defining Accessories and Classification Pathway for New Accessory Types Draft Guidance for Industry and Food and Drug Administration Staff This guidance document is being distributed

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Cooperative Manufacturing Arrangements for Licensed Biologics DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding

More information

Pharmaceutical Intellectual Property Summit Biosimilars Panel. Janis Fraser, moderator October 28, 2010 Princeton, NJ

Pharmaceutical Intellectual Property Summit Biosimilars Panel. Janis Fraser, moderator October 28, 2010 Princeton, NJ Pharmaceutical Intellectual Property Summit Biosimilars Panel Janis Fraser, moderator October 28, 2010 Princeton, NJ Pharmaceutical Intellectual Property Summit Biosimilars Panel Terry G. Mahn October

More information

Please note that these flowcharts and checklists are from the IRB Researcher Manual.

Please note that these flowcharts and checklists are from the IRB Researcher Manual. Hello Researcher: Please use the following flowcharts and checklists to help you determine when your research may require a review by the Institutional Review Board (IRB). Please note that these flowcharts

More information

The U.S. prescription drug market is complex and,

The U.S. prescription drug market is complex and, EASY EXPLAINER NO. 13 DECEMBER 2017 Prescription Drug Competition Hampered by Policies, Barriers and Delay Tactics The U.S. prescription drug market is complex and, for a variety of reasons, lacks the

More information

I N S I D E T H E M I N D S

I N S I D E T H E M I N D S I N S I D E T H E M I N D S Recent Developments in Food and Drug Law Leading Lawyers on Dealing with Increased Enforcement, Keeping Up-To-Date with FDA Requirements, and Developing Compliance Practices

More information

GUIDELINES FOR REGISTRATION OF IMPORTERS AND FOR THE IMPORTATION OF MEDICINES AND RELATED PRODUCTS

GUIDELINES FOR REGISTRATION OF IMPORTERS AND FOR THE IMPORTATION OF MEDICINES AND RELATED PRODUCTS MEDICINES CONTROL AGENCY 54 Kairaba Avenue, Pipeline, The Gambia. Tel.no. +220 4380632 GUIDELINES FOR REGISTRATION OF IMPORTERS AND FOR THE IMPORTATION OF MEDICINES AND RELATED PRODUCTS Document no: MCA/IMPG/2017/1

More information

FDA PLANS TO REGULATE TESTS AS DEVICES. August 2010 SPECIAL REPRINT. By Ellen Flannery and Scott Danzis

FDA PLANS TO REGULATE TESTS AS DEVICES. August 2010 SPECIAL REPRINT. By Ellen Flannery and Scott Danzis August 2010 SPECIAL REPRINT FDA PLANS TO REGULATE LABORATOR ORY DEVELOPED TESTS AS DEVICES By Ellen Flannery and Scott Danzis Reproduced with the kind permission of Global Regulatory Press from the Journal

More information

American Heart Association/American Stroke Association Statement on Drug Formularies

American Heart Association/American Stroke Association Statement on Drug Formularies American Heart Association/American Stroke Association Statement on Drug Formularies Underlined terms are defined on page 4 of the document. 1. The AHA supports a formulary system that: Assures access

More information

Theodore Sullivan Partner Quarles & Brady LLP (Washington, DC)

Theodore Sullivan Partner Quarles & Brady LLP (Washington, DC) Rachael Pontikes Partner Duane Morris LLP (Chicago, IL) Theodore Sullivan Partner Quarles & Brady LLP (Washington, DC) Moderator: Brian Malkin Counsel Arent Fox LLP (Washington, DC) 1 Legality of Animal

More information

HCT/P Regulation vs 361 Products

HCT/P Regulation vs 361 Products HCT/P Regulation - 351 vs 361 Products Presented by: Paul Gadiock February 15, 2017 Arent Fox LLP Washington, DC New York, NY Los Angeles, CA San Francisco, CA 1 Presentation Overview Introduction Public

More information

A critical review of the current landscape Presentations

A critical review of the current landscape Presentations CLINICAL INNOVATION: Fair & Effective Incentives for New Uses of Established Drugs A critical review of the current landscape Presentations Presenters: Christoph de Coster Taylor Wessing LLP Elaine Herrmann

More information

75th OREGON LEGISLATIVE ASSEMBLY Regular Session. Enrolled. Senate Bill 676 CHAPTER... AN ACT

75th OREGON LEGISLATIVE ASSEMBLY Regular Session. Enrolled. Senate Bill 676 CHAPTER... AN ACT 75th OREGON LEGISLATIVE ASSEMBLY--2009 Regular Session Sponsored by Senators PROZANSKI, NELSON Enrolled Senate Bill 676 CHAPTER... AN ACT Relating to industrial hemp; creating new provisions; amending

More information

INVESTIGATIONAL DEVICES & DRUGS. What is an IRB to do?

INVESTIGATIONAL DEVICES & DRUGS. What is an IRB to do? INVESTIGATIONAL DEVICES & DRUGS What is an IRB to do? What is a medical device? An instrument, apparatus, implement, machine, contrivance, implant, or in vitro diagnostic reagent Recognized in the official

More information

Kirsten L. Vadheim, Ph.D. BioCompliance Consulting, Inc. Presented at the ASBM Forum, February 25, 2014, Washington DC

Kirsten L. Vadheim, Ph.D. BioCompliance Consulting, Inc. Presented at the ASBM Forum, February 25, 2014, Washington DC Kirsten L. Vadheim, Ph.D. BioCompliance Consulting, Inc. Presented at the ASBM Forum, February 25, 2014, Washington DC klvadheim@hotmail.com The Importance of Data Over Time 2003: FDA approved innovator

More information

SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2055

SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2055 Brief* SESSION OF 2017 SUPPLEMENTAL NOTE ON HOUSE BILL NO. 2055 As Recommended by House Committee on Health and Human Services HB 2055 would amend the Kansas Pharmacy Act (Act) by deleting, adding, and

More information

Republic of the Philippines Department of Health OFFICE OF THE SECRETARY M a n i l a

Republic of the Philippines Department of Health OFFICE OF THE SECRETARY M a n i l a Republic of the Philippines Department of Health OFFICE OF THE SECRETARY M a n i l a March 15, 1989 ADMINISTRATIVE ORDER No. 67 s. 1989 SUBJECT: Revised Rules and Regulations on Registration of Pharmaceutical

More information

USE OF INVESTIGATIONAL DRUGS OR BIOLOGICS IN HUMAN SUBJECTS RESEARCH

USE OF INVESTIGATIONAL DRUGS OR BIOLOGICS IN HUMAN SUBJECTS RESEARCH Policy P.11 Written By: B. Laurel Elder Created: June 3, 2013 Edited Replaces 10-9-2009 Version P.11.4 USE OF INVESTIGATIONAL DRUGS OR BIOLOGICS IN HUMAN SUBJECTS RESEARCH A. Procedure Contents this procedure

More information

Import Admissibility Process. Russell Vandermark Consumer Safety Officer FDA Philadelphia District Import Operations Group

Import Admissibility Process. Russell Vandermark Consumer Safety Officer FDA Philadelphia District Import Operations Group Import Admissibility Process Russell Vandermark Consumer Safety Officer FDA Philadelphia District Import Operations Group Prescription Finished Dosages Drug Approval New Drug Application Entry Validation

More information

An Introduction to Health Care: Agencies, Laws and Regulations

An Introduction to Health Care: Agencies, Laws and Regulations An Introduction to Health Care: Agencies, Laws and Regulations Association of Corporate Counsel December 5, 2017 Lawrence W. Vernaglia Partner & Chair, Health Care Industry Team Foley & Lardner LLP Boston,

More information

Guidelines: c. Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical

Guidelines: c. Providing the investigational drug for the requested use will not interfere with the initiation, conduct, or completion of clinical Guidelines for the Submission of an Expanded Access IND to Permit Diagnosis, Monitoring or Treatment of Intermediate-size Patient Populations with an Investigational Drug or a REMS-restricted, Approved

More information

Paths to Market & FDA Product Lifecycle Regulation. Patricia Kaeding Design of Medical Devices University of Minnesota April 14, 2005

Paths to Market & FDA Product Lifecycle Regulation. Patricia Kaeding Design of Medical Devices University of Minnesota April 14, 2005 Paths to Market & FDA Product Lifecycle Regulation Patricia Kaeding Design of Medical Devices University of Minnesota April 14, 2005 FDA Organization U.S. Food & Drug Administration Headed by a Commissioner

More information

Yes, You Can Teach an Old Drug New Tricks: Regulatory Pathway for Repurposed Drugs

Yes, You Can Teach an Old Drug New Tricks: Regulatory Pathway for Repurposed Drugs Yes, You Can Teach an Old Drug New Tricks: Regulatory Pathway for Repurposed Drugs 1 Kurt R. Karst Hyman, Phelps & McNamara, P.C. March 17, 2017 Agenda Drug Repurposing What is it? And why do it? Regulatory

More information

An Overview of FDA Regulation: What the Canadian Biomedical Industry Needs to Know

An Overview of FDA Regulation: What the Canadian Biomedical Industry Needs to Know An Overview of FDA Regulation: What the Canadian Biomedical Industry Needs to Know Montreal, Canada November 8, 2006 Presented by: John Will Ongman, Esq. 1801 K Street, N.W. Suite 411 Washington, D.C.

More information

Guidance for Industry Compounding Animal Drugs from Bulk Drug Substances

Guidance for Industry Compounding Animal Drugs from Bulk Drug Substances #230 Guidance for Industry Compounding Animal Drugs from Bulk Drug Substances DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this

More information

Pharmabiotics: a Regulatory Hurdle in Europe

Pharmabiotics: a Regulatory Hurdle in Europe Pharmabiotics: a Regulatory Hurdle in Europe Dr. Magali Cordaillat-Simmons PRI Executive Scientist Raleigh, NC, USA September 8th, 2014 PHARMABIOTICS: A REGULATORY HURDLE IN EUROPE I. Introduction to Pharmabiotics

More information

Science & Research. Frequently Asked Questions. 1 of 6 7/8/ :52 PM

Science & Research. Frequently Asked Questions.  1 of 6 7/8/ :52 PM 1 of 6 7/8/2010 11:52 PM Home > Science & Research > Science and Research Special Topics > Nanotechnology Science & Research Frequently Asked Questions 1. What is nanotechnology? While many definitions

More information

CATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity

CATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity CATEGORY Advertising Guidance Agenda: New & Guidances CDER is Planning to Publish During Calendar Year 2016 (See the Good Guidance Practices (GGPs) regulation on this Web page or 21 CFR 10.115 for details

More information

CBER Regulatory Updates: Initiatives for Product Review and Licensure

CBER Regulatory Updates: Initiatives for Product Review and Licensure CBER Regulatory Updates: Initiatives for Product Review and Licensure CASSS CMC Strategy Forum Japan 2018 December 3, 2018 Robin Levis, Ph.D. Division of Viral Products Office of Vaccines Research and

More information

Subpart H [Reserved] Subpart I Expanded Access to Investigational Drugs for Treatment. 21 CFR Ch. I ( Edition)

Subpart H [Reserved] Subpart I Expanded Access to Investigational Drugs for Treatment. 21 CFR Ch. I ( Edition) 312.300 (c) Disposition of unused drug. The person who ships the drug under paragraph (a) of this section shall assure the return of all unused supplies of the drug from individual investigators whenever

More information

Regulation of Cell and Gene Therapy Products in Canada

Regulation of Cell and Gene Therapy Products in Canada Regulation of Cell and Gene Therapy Products in Canada Canadian Blood and Bone Marrow Transplant Group June 8, 2018 Nadine Kolas, PhD Senior Policy Analyst Blood, Cells, Tissues and Organs Biologics and

More information

Main Content Domain % of Operational Items # of Operational Items

Main Content Domain % of Operational Items # of Operational Items The PCOA content areas and subtopics for the 2016-2017 administration are based upon the outcomes from the US College of Pharmacy Curricula Survey. The assessment is composed of four content areas that

More information

Defining Clinical Benefit in Clinical Trials: FDA Perspective

Defining Clinical Benefit in Clinical Trials: FDA Perspective Defining Clinical Benefit in Clinical Trials: FDA Perspective Jessica J. Lee, MD, MMSc Medical Team Leader Division of Gastroenterology and Inborn Errors Products Center for Drug Evaluation and Research

More information

Drug Products, Labeling, and Packaging

Drug Products, Labeling, and Packaging 442 Pharmaceutical Industry: Drug Products, Labeling, and Packaging Positions Drug Products, Labeling, and Packaging Ready-to-Administer Packaging for Hazardous Drug Products Intended for Home Use (1711)

More information

Policy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)

Policy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Geneva, April 2016 Appropriate use of biotherapeutics including SBPs - SBPs, also known as biosimilars, are developed to

More information

What s the fuss with compounding. Fuss [2] Pharmaceutical Compounding. Pharmaceutical Compounding: Learning Objectives

What s the fuss with compounding. Fuss [2] Pharmaceutical Compounding. Pharmaceutical Compounding: Learning Objectives Pharmaceutical Compounding Legal Requirements and Good Compounding Practices Tom Hazlet Autumn 2005 Pharmaceutical Compounding: Learning Objectives Describe the historical precedents and incidents that

More information

Please note that these flowcharts and checklists are from the IRB Researcher Manual.

Please note that these flowcharts and checklists are from the IRB Researcher Manual. Hello Researcher: Please use the following flowcharts and checklists to help you determine when your research may require a review by the Institutional Review Board (IRB). Please note that these flowcharts

More information